Comparing Jupiter Neurosciences (NASDAQ:JUNS) & Traws Pharma (NASDAQ:TRAW)

Jupiter Neurosciences (NASDAQ:JUNS) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Valuation and Earnings

This table compares Jupiter Neurosciences and Traws Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20,000.00	117.39	-$8.65 million	($19.12)	-0.13
Traws Pharma	$2.79 million	3.45	$9.17 million	($1.74)	-0.36

Traws Pharma has higher revenue and earnings than Jupiter Neurosciences. Traws Pharma is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Jupiter Neurosciences has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Institutional and Insider Ownership

8.0% of Traws Pharma shares are owned by institutional investors. 38.6% of Jupiter Neurosciences shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Jupiter Neurosciences and Traws Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%
Traws Pharma	N/A	-23,868.92%	-165.52%

Analyst Recommendations

This is a summary of current ratings and price targets for Jupiter Neurosciences and Traws Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1	0	0	0	1.00
Traws Pharma	1	4	0	0	1.80

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 59.74%. Given Traws Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than Jupiter Neurosciences.

Summary

Traws Pharma beats Jupiter Neurosciences on 7 of the 12 factors compared between the two stocks.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.